Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Haematological cancer

Newly diagnosed AML: quizartinib improves OS

Nature Reviews Clinical Oncology volume 20, page 504 (2023)Cite this article

Subjects

Access through your institution
Buy or subscribe

FLT3 internal tandem duplication (FLT3-ITD) occurs in ~25% of patients with acute myeloid leukaemia (AML) and confers a poor prognosis. New data from the phase III QuANTUM-First trial demonstrate that adding the selective FLT3 inhibitor quizartinib to first-line therapy for this subset of patients improves overall survival (OS).

In QuANTUM-First, 539 patients aged 20–75 years with FLT3-ITD+ AML were randomly assigned (1:1) to receive quizartinib or placebo during standard induction chemotherapy,  and in those with complete remission (CR) or CR with incomplete neutrophil or platelet recovery (CRi), also during and for up to 3 years after consolidation therapy. OS from the time of randomization was the primary end point.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

  • Erba, H. P. et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401, 1571–1583 (2023)

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    David Killock

Authors
  1. David Killock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Killock.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Killock, D. Newly diagnosed AML: quizartinib improves OS. Nat Rev Clin Oncol 20, 504 (2023). https://doi.org/10.1038/s41571-023-00787-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-023-00787-6

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer